What Is Atorvastatin and How Does It Inhibit HMG-CoA Reductase?
Atorvastatin is the active ingredient in Lipitor, a statin drug that inhibits HMG-CoA reductase, the enzyme controlling the rate-limiting step in cholesterol biosynthesis. This pathway starts with acetyl-CoA converting to HMG-CoA, then to mevalonate, and proceeds to cholesterol. Inhibition reduces mevalonate production, slashing hepatic cholesterol synthesis by 30-50% at standard doses.[1]
Is There a Difference Between Atorvastatin and Lipitor?
No. Lipitor is the brand name for atorvastatin calcium developed by Pfizer. They are chemically identical; generic atorvastatin matches Lipitor's HMG-CoA reductase inhibition potency, pharmacokinetics, and cholesterol-lowering effects. Clinical trials show equivalent LDL reductions of 40-60%.[2]
How Much Does It Reduce Cholesterol Synthesis?
Atorvastatin blocks over 90% of HMG-CoA reductase activity in liver cells at therapeutic doses (10-80 mg daily). This drops total cholesterol synthesis by 20-40% overall, with greater impact on LDL cholesterol. The liver compensates by upregulating LDL receptors, clearing more circulating LDL.[1][3]
What Happens in the Body After Inhibition?
Downstream effects include lower isoprenoid intermediates, reducing inflammation and plaque buildup. Unlike less potent statins like simvastatin, atorvastatin sustains inhibition longer due to its active metabolites and lipophilicity, achieving deeper synthesis suppression.[3]
How Does It Compare to Other Statins?
Atorvastatin outperforms lovastatin or pravastatin in potency, inhibiting synthesis 1.5-2x more effectively at equipotent doses. Against rosuvastatin (Crestor), effects are similar, but atorvastatin has broader pleiotropic benefits.[3]
Sources
[1]: DrugPatentWatch.com - Atorvastatin Patents and Mechanism
[2]: FDA Orange Book - Atorvastatin Approvals
[3]: PubMed - Statin Mechanisms Review